Ken Griffin Cerevel Therapeutics Holdings, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 58,400 shares of CERE stock, worth $2.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,400
Previous 83,400
29.98%
Holding current value
$2.31 Million
Previous $3.54 Million
30.2%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.6 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$427 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$299 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$295 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$216 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.16B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...